Physician profile
Nichelle Renk
NPI 1548300205
$5,326.48
in general payments reported to CMS, 2019-2025
24 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $524 · 2021: $864 · 2022: $1,042 · 2023: $537 · 2024: $397 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325 · Consulting Fee: $84.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.74 |
| Consulting Fee | $84.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,682.54 | 2019-2024 | Senza |
| Avanos Medical | $891.10 | 2019-2025 | Generator, Coolief Cooled Radiofrequency, Standard Rf Disposables |
| Abbvie INC. | $607.97 | 2021-2025 | |
| Pfizer INC. | $258.12 | 2019-2025 | |
| Medtronic, INC. | $257.95 | 2022-2025 | Accurian, Kyphon Express II Kyphopak Tray |
| Merz Pharmaceuticals, LLC | $193.73 | 2021-2024 | Xeomin |
| Allergan, INC. | $189.81 | 2019-2022 | |
| Pacira Therapeutics, INC. | $155.70 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.76 | 2022 | |
| Merz North America, INC. | $122.60 | 2019-2020 | |
| Abbott Laboratories | $121.65 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $103.29 | 2020-2021 | |
| Lundbeck LLC | $84.32 | 2023-2025 | Vyepti |
| Amgen INC. | $79.82 | 2019-2022 | |
| Grt US Holding, INC. | $74.57 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $73.28 | 2020-2021 | |
| Averitas Pharma INC. | $66.84 | 2025 | Qutenza |
| Globus Medical, INC. | $51.28 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $40.05 | 2020-2025 | Ajovy |
| Tersera Therapeutics LLC | $33.44 | 2025 | Quzyttir |
| Si-Bone, INC. | $32.43 | 2020 | |
| Boston Scientific Corporation | $27.78 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.20 | 2019 | |
| Stimwave Technologies Incorporated | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichelle Renk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.